Analyst Reco. Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Real-time Estimate Cboe BZX Other stock markets 10:02:12 2024-04-26 am EDT			5-day change	1st Jan Change
21.44 ^USD	-0.72%		-9.37%	-20.43%

Apr. 04	Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	MT
Apr. 04	Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	Apr. 04	MT
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	Feb. 28	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	Feb. 28	MT
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	Feb. 27	MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	Jan. 29	MT
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	Dec. 15	MT
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75	Dec. 08	MT
Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating	23-10-17	MT
Credit Suisse Adjusts Beam Therapeutics' Price Target to $47 From $46, Keeps Neutral Rating	23-08-09	MT
Citigroup Adjusts Beam Therapeutics Price Target to $56 From $60, Maintains Buy Rating	23-08-09	MT
RBC Cuts Beam Therapeutics' Price Target to $32 From $42, Keeps Sector Perform Speculative Risk Rating	23-07-07	MT
Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating	23-05-11	MT
Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating	23-05-11	MT
RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating	23-05-11	MT
Bernstein Initiates Beam Therapeutics at Market Perform With $37 Price Target	23-03-21	MT
Wells Fargo Adjusts Price Target on Beam Therapeutics to $105 From $125, Keeps Overweight Rating	23-03-01	MT
Cantor Fitzgerald Starts Beam Therapeutics at Overweight With $62 Price Target	23-02-01	MT
SVB Securities Trims Price Target on Beam Therapeutics to $77 From $81, Maintains Outperform Rating	23-01-23	MT
BMO Capital Upgrades Beam Therapeutics to Outperform From Market Perform, Raises Price Target to $66 From $61	22-12-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 02:21 pm EST